Who founded AltrixBio?

AltrixBio was founded by Ali Tavakkoli, Nancy Briefs, Jeff Karp.

Who are AltrixBio's investors?

AltrixBio's investors include Service Provider Capital, Walnut Venture Associates.

How much funding has AltrixBio raised?

AltrixBio has disclosed $7.8M raised across 2 rounds.

Where is AltrixBio headquartered?

AltrixBio is headquartered in Wilmington, US.

AltrixBio

Wilmington, US · 2 known investors

Find your way into AltrixBio

66 people in our graph share verified history with the AltrixBio team — schools, employers, funds. One of them is your warm intro.

Tuoyo Louisunlockedknows Nancy Briefs · together at InfoBionic, Inc. (overlapped)

×11knows the team · via Golden Gate University

AltrixBio develops AJN003, a non-systemic, once-daily oral therapy for type 2 diabetes and related metabolic conditions that transiently coats the stomach and upper intestine to shift nutrient sensing and trigger a metabolic reset similar to bariatric surgery. The drug targets glycemic control and weight loss and is positioned as a complement or alternative to incretin-based (GLP-1) treatments, with potential applications in broader cardiometabolic diseases.

Biotech Digital Health

Founders & leadership

Ali TavakkoliCo-founder

Nancy Briefs inExecutive Chair of the Board & FounderNancy Briefs is Executive Chair and Founder of AltrixBio, a biotech company developing an oral therapy for type 2 diabetes and metabolic conditions. She brings experience as a board member and former CEO in digital health, medical devices, and pharmaceuticals, with a track record of raising capital and achieving multiple exits across portfolio companies.

Jeff KarpCo-founder

Board

John BrooksBoard director

Investors · 2

Service Provider CapitalVail

Walnut Venture AssociatesWellesley

Reported raises · per SEC filings

Form D private placements

$7.8M disclosed across 2 rounds · 2019–2025

▶$1.2MraisedJun 2025 · 20 investors · Pharmaceuticals

Rule 506(c)

Officers, directors & promoters on the filing

John BrooksDirector
Jeffrey KarpDirector
Ali TavakkoliDirector
Nancy BriefsExecutive Officer, Director

Offering amount: $10M
Amount sold: $1.2M
Minimum investment: $10K
Finders' fees: $250K
Proceeds to insiders: $75K
First sale: Apr 2025
Incorporated: Corporation, Delaware
Federal exemptions: 04, 06c, 4a5

Full filing on SEC EDGAR ↗

▶$6.6MraisedJun 2025 · 50 investors · Pharmaceuticals

Rule 506(c)

Officers, directors & promoters on the filing

Jeffrey KarpDirector
Nancy BriefsExecutive Officer, Director
Ali TavakkoliDirector
John BrooksDirector

Offering amount: $6.6M
Amount sold: $6.6M
Minimum investment: $10K
First sale: Mar 2019
Incorporated: Corporation, Delaware
Federal exemptions: 04, 06c, 4a5

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

Bioworld21 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Myricx Bio13 shared keywordsMyricx Bio is a biotech company developing antibody drug conjugates (ADCs) based on N-myristoyltransferases (NMT) inhibitors for cancer treatment. The company focuses on discovering novel payloads to address unmet oncology needs.

Regenx Biosciences13 shared keywordsREGENXBIO is a gene therapy company developing treatments for rare and retinal diseases using its NAV Technology Platform of viral vectors, which it also licenses to other pharmaceutical and biotech companies. It operates a late-stage clinical pipeline and manufactures its investigational gene therapies at its facility in Rockville, MD.

Companies competing with AltrixBio for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

AltrixBio Raises $5 Million Series A Financing and Appoints David Pass as CEO to Advance Lead Candidate into the Clinicprnewswire.com · Sep 2025

AltrixBio Raises $5M in Series A Fundingfinsmes.com · Sep 2025

About AltrixBio - AltrixBioaltrixbio.com · Sep 2025

Frequently asked questions

What does AltrixBio do?: AltrixBio develops AJN003, a non-systemic, once-daily oral therapy for type 2 diabetes and related metabolic conditions that transiently coats the stomach and upper intestine to shift nutrient sensing and trigger a metabolic reset similar to bariatric surgery. The drug targets glycemic control and weight loss and is positioned as a complement or alternative to incretin-based (GLP-1) treatments, with potential applications in broader cardiometabolic diseases.
Who founded AltrixBio?: AltrixBio was founded by Ali Tavakkoli, Nancy Briefs, Jeff Karp.
Who are AltrixBio's investors?: AltrixBio's investors include Service Provider Capital, Walnut Venture Associates.
How much funding has AltrixBio raised?: AltrixBio has disclosed $7.8M raised across 2 rounds.
Where is AltrixBio headquartered?: AltrixBio is headquartered in Wilmington, US.